Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
about
Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
description
scientific article published on 14 December 2018
@en
name
Cetuximab monotherapy and cetu ...... nter phase II trial SAKK 41/10
@en
type
label
Cetuximab monotherapy and cetu ...... nter phase II trial SAKK 41/10
@en
prefLabel
Cetuximab monotherapy and cetu ...... nter phase II trial SAKK 41/10
@en
P2093
P1476
Cetuximab monotherapy and cetu ...... nter phase II trial SAKK 41/10
@en
P2093
Alessandro Lugli
Christiane Andrieu
Daniel Dietrich
Daniel Helbling
Daniel Horber
Daniela Baertschi
Dieter Koeberle
Dirk L Kienle
Juerg Bernhard
Karin Ribi
P304
P356
10.1016/J.JGO.2018.11.011
P577
2018-12-14T00:00:00Z